Endocrine Abstracts

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the efficacy of dapagliflozin in type 2 diabetic patients. We evaluated the efficacy and safety of body weight reduction of dapagliflozin in real practice with type 2 diabetes in Korea.

Methods: This is a retrospective, observational study, data from 61 patients with 12 months of dapagliflozin (10 mg once-daily) therapy were analyzed, visited medical center from January 2015 to July 2016. We had divided into three treatment groups: first group taking combination of dapagliflozin and metformin (Group 1); second group taking triple combination of dapagliflozin and metformin with sulfonylurea or dipeptidyl-peptidase IV (DPP-4) inhibitors (Group 2); third group taking quadriple combination of dapagliflozin, metformin and sulfonylurea with DPP-4 inhibitors (Group 3).

Results: After 12 months, mean change from baseline body weight was −3.4±2.6 kg (P<0.001) for total, −3.4±3.1 kg (P<0.001) for group 1, −2.7±2.0 kg (P=0.008) for group 2, −4.0±2.3 kg (P<0.001) for group 3. In total, mean change from baseline SBP and DBP were −6.0±14 mmHg (P=0.001) and −3.4±7.7 mmHg (P=0.002) respectively. Patients who achieved body weight reduction of ≥5% after 12 months were classified in the responder group and<5% non-responder group. There were baseline fasting C-peptide level was higher in responder group than non-responder group (3.25±1.07 ng/ml vs. 2.62±1.02 ng/ml, P=0.023). In total, reductions in HbA1c and PP2 glucose levels were −0.61±0.82% (P<0.001) and −35.4±62 mg/dl (P<0.001) respectively. There were no serious adverse event including hypoglycemia in dapagliflozin group.

Conclusions: In patients with type 2 diabetes, SGLT-2 inhibitor improved glycemic control and reduced body weight reduction with safety of dapagliflozin.